-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Neutral on Iovance Biotherapeutics, Raises Price Target to $8

Benzinga·11/03/2026 16:01:32
Listen to the news
UBS analyst David Dai maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Neutral and raises the price target from $7 to $8.